Roger S. Blumenthal, MD, FACC
Professor of Medicine
Director, The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease
Johns Hopkins Hospital
Gary Owens, MD
Gary Owens Associates
Medical Management and Pharmaceutical Consulting
Glen Mills, PA
Physicians CME: 1 credit
Pharmacists CPE: 1 contact hour (0.1 CEU) Medium
THIS ACTIVITY WAS ORIGINALLY PRESENTED AS AN AUDIOCONFERENCE SERIES BEGINNING ON SEPTEMBER 23, 2009. IF YOU EARNED CME/CE CREDIT FOR AN AUDIOCONFERENCE PRESENTATION YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE RELEASE.
Cardiovascular disease remains a leading killer in the United States, and epidemiologic studies continue to show a direct relationship between atherosclerosis and coronary heart disease (CHD). A quality improvement initiative revealed that patients with cardiac risk equivalents often are not being treated appropriately by clinicians; they are receiving less than optimal care. Recent clinical data released at the American Heart Association have stirred significant debate among cardiologists and other clinicians. As research improves our understanding of dyslipidemia, cardiac inflammation, endothelial dysfunction, and atherosclerosis, managed care professionals need continuing education that will help them implement appropriate strategies and prevention plans that will improve clinical outcomes in patients with cardiovascular disease. Program Developer/Facilitator
. Target Audience
Managed care medical directors, pharmacy directors, physicians, pharmacists and other managed care professionals.
Upon completion of this educational activity, the participant should be able to:
Describe how effective primary and secondary cardiovascular prevention strategies can reduce the healthcare burden associated with elevated LDL-C and atherosclerosis.
Evaluate recent developments in the understanding and application of cardiovascular risk assessment, including limitations of various risk assessment tools.
Review the data on pharmacologic therapies used to treat elevated LDL-C and atherosclerosis.
Outline managed care strategies to effectively improve cardiovascular clinical outcomes using effective prevention strategies.
It is the policy of the accredited providers to ensure balance, independence, objectivity and scientific rigor in all of its continuing education programs. Faculty must disclose to program participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial products discussed in an educational presentation.
Dr. Blumenthal discloses that he has no current financial relationships with commercial interests and/or the opportunity to affect content relevant to the products or services of those commercial interests.
Dr. Owens discloses that: he has received honoraria for serving as a consultant to Eli Lilly, BioSense Webster, Novartis, Asthmatx, AstraZeneca, and Wyeth; he has served on advisory boards for Eli Lilly, Novartis, ImClone Systems, Roche Pharmaceuticals, sanofi aventis, and Wyeth; and he has participated in market research for AstraZeneca.
Please note: The opinions expressed in this program should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this program may include the use of drugs for unlabeled indications. Use of drugs outside of labeling should be considered experimental, and participants are advised to consult prescribing information and professional literature. Credit Statements
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the National Association of Managed Care Physicians (NAMCP) and Medical Communications Media, Inc. The NAMCP is accredited by the ACCME to provide continuing medical education to physicians.
NAMCP designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Pharmacists: ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 221-999-09-059-H01-P has been assigned to this online program (initial release date 11-15-09). This program is approved for 1.0 contact hours (0.10 CEUs) in states that recognize ACPE providers. The program is provided at no cost to participants. Statements of credit will be available immediately online following the program. Participants must attend the entire program, complete a program evaluation form, and complete a post-test with a score of 70% or higher to receive pharmacy CE credit. No partial credit will be given. Commercial Support Statements
Please turn off all pop-up blockers.
Click on the "Start program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new cmecorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
Complete the short survey and click on "done."
The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. This activity will require approximately 60 minutes to complete.
After the program has finished, click on the "Post-test" button. Complete the short survey and click on "done."
Instructions for completing and submitting the post-test and program evaluation are provided on the post-test screen. A credit certificate will be awarded for a score of 70% or better and may be printed immediately after passing the post-test.